miércoles, 24 de marzo de 2010

Tony "Hood" no, Zook (AstraZeneca) y sus planes "neocolonialistas"..."(II)

Click sobre imagen para ampliar

In 2006, IMS identified seven pharmerging markets – China, Brazil, Mexico, India, Russia, South Korea and Turkey . In its latest study, the firm identifies three levels of such markets -

Tier I
of which consists solely of China.

The Tier II pharmerging markets are Brazil, Russia and India, which are each expected to add $5-$15 billion in annual pharmaceutical sales by 2013. Brazil and Russia have both achieved consistent double-digit pharmaceutical sales growth in recent years, while India has benefited from a rising middle-class population, improvements in medical infrastructure and the establishment of intellectual property rights, says the report.

Finally Tier III consists of what IMS terms the “fast followers” - an additional 13 countries which are now expected to contribute $1-$5 billion
each in annual sales growth by 2013. They are: Venezuela, Poland, Argentina, Turkey, Mexico, Vietnam, South Africa, Indonesia, Romania, Egypt, Pakistan,Thailand and the Ukraine. While each market is unique, they are all complex, dynamic and subject to rapid change, according to the study.

Ver anterior

Fuente IMS

No hay comentarios: